However, for patients at very high risk, including those with atherosclerotic cardiovascular disease (ASCVD), the use of the combination therapy of statins, ezetimibe and a PCSK9 inhibitor would result in approximately 90% of patients achieving their risk-based LDL-C goals. The gene discussed is PCSK9; the disease is atherosclerosis.